Moberg Pharma AB (publ)
STO:MOB
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| SE |
|
Moberg Pharma AB (publ)
STO:MOB
|
430.1m SEK |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
982.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
292.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
240.1B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
247.3B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
302.6B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.1B USD |
Loading...
|
|
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
91B GBP |
Loading...
|
Market Distribution
| Min | -855 316.7% |
| 30th Percentile | 30.8% |
| Median | 44.8% |
| 70th Percentile | 66% |
| Max | 113 764.6% |
Other Profitability Ratios
Moberg Pharma AB (publ)
Glance View
Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Moberg Pharma AB (publ) is 52.3%, which is below its 3-year median of 71.1%.
Over the last 3 years, Moberg Pharma AB (publ)’s Gross Margin has decreased from 100% to 52.3%. During this period, it reached a low of 52.3% on Oct 30, 2025 and a high of 100% on Jun 30, 2023.
